Glucosylceramidase (GBA1) (GBA1)

Lysosomal beta-glucocerebrosidase, also known as glucosylceramidase or GCase, is a critical housekeeping enzyme encoded by the GBA1 gene that resides within the lysosome [UniProt P04062]. Its primary biological function is the hydrolysis of glucosylceramide into glucose and ceramide, a vital step in the sphingolipid metabolic pathway. Deficiency of this enzyme leads to the systemic accumulation of glucosylceramide, particularly within macrophages, resulting in Gaucher disease [NIH StatPearls: Gaucher Disease]. Gaucher disease is characterized by hepatosplenomegaly, cytopenia, and skeletal complications. Furthermore, GBA1 mutations are the most common genetic risk factor for Parkinson's disease and Lewy body dementia, as enzyme dysfunction promotes the aggregation of alpha-synuclein [PubMed: 26084051]. Current therapeutic strategies include enzyme replacement therapies (ERTs) such as imiglucerase and velaglucerase alfa, which provide exogenous enzyme to alleviate peripheral symptoms. Research is actively pursuing pharmacological chaperones, small molecule activators, and gene therapies to address the neurological manifestations that remain a significant therapeutic challenge [PubMed: 30530502].

Other names

Acid beta-glucosidaseGlucocerebrosidaseGCaseGBA1D-glucosyl-N-acylsphingosine glucohydrolase

Enzyme replacement therapy (ERT) provides exogenous functional enzyme to catalyze substrate breakdown [PubMed: 24053971]. Pharmacological chaperone therapy (PCT) stabilizes misfolded mutant enzymes to improve lysosomal trafficking [PubMed: 28107179]. Gene therapy restores endogenous enzyme production via viral vector delivery [PubMed: 30530502].